A file photo showing the EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in Washington
(Copyright Reuters 2016)
WASHINGTON – The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said Tuesday.
Mylan to pay $465M settlement over Medicaid EpiPen rebates
Lawmakers lash out at Mylan over EpiPen profit revision
Parent bloggers question role in Mylan’s EpiPen schools push
In a press release, Grassley’s office said the HHS Inspector General confirmed in discussions with Senate aides that the watchdog office notified the Centers for Medicare and Medicaid Services about the problematic classification, which was highlighted in a report.
Mylan has since said it intends to pay $465 million to settle with the U.S. Justice Department over charges …
Go to Source